We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Avacta Group Plc | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.75 | 1.53% | 49.75 | 49.50 | 50.00 | 49.75 | 47.50 | 48.75 | 3,399,639 | 16:13:35 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 10.06M | -39.19M | -0.1382 | -3.60 | 141.1M |
TIDMAVCT
Avacta Group PLC
12 November 2018
12 November 2018
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Avacta's Chief Scientific Officer to Present Recent Data at Major European Conference
Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents, is pleased to announce that its Chief Scientific Officer, Dr Amrik Basran, will be presenting at the Protein Engineering Society of Europe meeting, which is taking place in Lisbon on 14 November 2018. Dr Basran will be presenting recent data relating to the pre-clinical development of the Group's lead therapeutic programme, a PD-L1/LAG-3 single molecule bispecific.
Dr Basran will focus particularly on the development of novel Affimer(R) bispecific formats that inhibit two immune checkpoints simultaneously. PD-L1 plays a key role in suppressing the immune system, and by blocking this checkpoint protein on tumour cells, it assists the immune system's attack on the cancer. The blocking of LAG-3 on T-cells helps to maintain the immune system attack and reduce T-cell exhaustion.
The Group is developing this single molecule bispecific therapy with a view to entering phase I clinical development in 2020, which will yield first-in-man clinical data for the Affimer(R) platform. Avacta is also building a pipeline of novel immuno-oncology Affimer(R) assets for clinical development and licensing.
- Ends -
For further information from Avacta Group plc, please contact:
Avacta Group plc Tel: +44 (0) 844 414 0452 Alastair Smith, Chief Executive Officer www.avacta.com Tony Gardiner, Chief Financial Officer finnCap Ltd Tel: +44 (0) 207 220 0500 Geoff Nash / Giles Rolls - Nominated www.finncap.com Adviser Tim Redfern - Corporate Broking Tel: +44 (0) 203 705 9318 WG Partners Tel: +44 (0) 203 705 9317 Nigel Birks / Nigel Barnes www.wgpartners.co.uk David Wilson / Claes Spang Zyme Communications (Trade and Regional Tel: +44 (0)7787 502 947 Media) katie.odgaard@zymecommunications.com Katie Odgaard Yellow Jersey (Financial Media and Tel: +44 (0)7764 947137 IR) Tel: +44 (0)7946 424 651 Sarah Hollins avacta@yellowjerseypr.com Katie Bairsto
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer(R) technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer(R) technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer(R) reagents through licensing to developers of life sciences research tools and diagnostics.
To register for news alerts by email go to www.avacta.com/investor-news-email-alerts
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NRAFSWFMUFASEIF
(END) Dow Jones Newswires
November 12, 2018 02:00 ET (07:00 GMT)
1 Year Avacta Chart |
1 Month Avacta Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions